Welcome to our dedicated page for FENNEC PHARMACEUTICALS SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), reported the release of 2,430 common shares from restrictions on 09/30/2025 at a reported price of $0, reflecting shares awarded previously on 03/31/2023 and 05/16/2024. After this transaction Andrade beneficially owns 170,674 common shares. The Form 4 was signed on 10/01/2025. The filing shows a routine internal release of restricted awards rather than an open-market purchase or sale and documents current insider ownership levels for compliance with Section 16 reporting.
Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), exercised stock options on 09/05/2025. He exercised 36,207 options with a $2.45 strike, resulting in 36,207 common shares acquired and increasing his total beneficial ownership to 87,293 shares. The options exercised had an exercise price of $2.45 and an expiration date of July 5, 2026; the filing lists a date exercisable of July 5, 2016. The Form 4 was signed on 09/08/2025 and reports the transaction as a direct ownership change by one reporting person.
Fennec Pharmaceuticals (FENC) Form 144 reports a proposed sale of 10,000 common shares through Morgan Stanley Smith Barney on 09/04/2025 with an aggregate market value of $89,220.00. The filing lists total outstanding shares of 27,831,698, showing the proposed block is a small fraction of the float.
The shares to be sold were acquired as restricted stock from the issuer: 7,570 shares on 05/16/2025 and 2,430 shares on 08/31/2025, totaling 10,000. The filer also disclosed three prior sales in the past three months of 10,000 shares each on 06/05/2025, 07/03/2025, and 08/05/2025 with gross proceeds of $77,781, $86,102, and $80,933 respectively.
Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a sale of 10,000 common shares on 09/04/2025 at a reported price of $8.92 per share. The Form 4 indicates the sale was made pursuant to a 10b5-1 plan dated August 23, 2024. Following the reported transaction, Mr. Raykov beneficially owns 51,086 shares, held directly. The filing is a routine insider reporting disclosure of this transaction.
Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals, reported a Form 4 disclosing a transaction dated 08/31/2025 in which 2,431 common shares were acquired at a reported price of $0. The filing explains these shares were released from restriction and are from awards originally granted on 3/31/2023 and 5/16/2024. After this transaction Andrade beneficially owns 168,244 common shares. The Form 4 was signed by Andrade on 09/02/2025. The disclosure is a routine insider vesting event rather than a cash market purchase or sale.
FENNEC PHARMACEUTICALS INC. (FENC) director Rosty Raykov reported a Form 4 disclosing a change in beneficial ownership on 08/31/2025. Mr. Raykov acquired 5,208 common shares at a reported price of $0, increasing his total beneficial ownership to 61,086 shares. The filing explains these shares were released from restriction and originate from equity awards granted on 03/31/2023 and 05/16/2024. The Form 4 was filed by one reporting person and is signed on 09/02/2025. No derivative transactions or cash purchases are reported; the activity reflects restricted share vesting or release rather than an open-market purchase.